Bio-Techne (TECH) announced a distribution agreement with the U.S. Pharmacopeia, or USP, that enables the company to sell USP monoclonal antibody and recombinant adeno-associated virus, or AAV, reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide. Maintaining consistent mAb quality is vital for their efficacy. Both USP mAbs and AAV reference standards provide stringent materials that can be used with Bio-Techne’s analytical instruments, such as the MauriceFlex system.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: